Product Name: KIT (933-939) pY936
Product Number: PE-04AZV00
Size: | 200 µg | | Price: | 35.00 |
| 1 mg | | $US | 70.00 |
Peptide Name: KIT (933-939) pY936
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the C-terminal of the kinase after the catalytic domain. Y936 phosphorylation induces interaction with APS, CBL, BRB2 and GRB7.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: NHI-pY-SNL
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 938.91 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Scientific Background: Kit (SCFR) is a protein-tyrosine kinase of the TK group and PDGFR family. It is a receptor kinase that binds SCF/KitLG. Mast,stem cell growth factor (steel factor) binding induces Kit dimerization and autophosphorylation. Protein interactions are induced with phosphorylation at Y568 (with APS, Cbl, SHP2, & Src), Y900 (with Crk & PIK3C2A) and Y936 (with APS, Cbl, Grb2 & Grb7). Phosphorylation of S741 and S746 inhibits the kinase activity of Kit. Kit can mediate cell proliferation, survival, hematopoiesis, gametogenesis, stem cell maintenance, mast cell development, function, and migration, as well as melanogenesis. Some substrates that Kit can phosphorylate include PIK3R1, PLCG1, SH2B2/APS and CBL.This kinase is highly expressed and widely distributed in most tested human tissues. It was first identified as the cellular homologue of the feline sarcoma viral oncogene v-kit. Mutations in Kit are associated with gastrointestinal stromal tumors (GIST), mast cell leukemia, acute myelogenous leukemia (AML), and piebaldism. Kit has also been linked with the development of colorectal adenocarcinomas and melanoma progression. Insertional mutagenesis studies in mice also support a role for this protein kinase in mouse cancer oncogenesis.